Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             127 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 Activity-based anorexia in C57/BL6 mice: Effects of the phytocannabinoid, △9-tetrahydrocannabinol (THC) and the anandamide analogue, OMDM-2 Lewis, David Y.
 2010
 20 Supplement 2 p. 622-631
10 p.
 artikel
2 Acute quetiapine dose-dependently exacerbates anhedonia induced by withdrawal from escalating doses of d-amphetamine Zhornitsky, Simon
 2010
 20 Supplement 2 p. 695-703
9 p.
 artikel
3 Adolescent escitalopram administration modifies neurochemical alterations in the hippocampus of maternally separated rats Hui, Jiaojie
 2010
 20 Supplement 2 p. 875-883
9 p.
 artikel
4 Blood–brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein Karlsson, Louise
 2010
 20 Supplement 2 p. 632-640
9 p.
 artikel
5 Cannabinoid self-administration attenuates PCP-induced schizophrenia-like symptoms in adult rats Spano, Maria Sabrina
 2010
 20 Supplement 2 p. 25-36
12 p.
 artikel
6 C.03.03 Clinical picture of an organic psychosis: Niemann-Pick type C Klunemann, H.H.
 2010
 20 Supplement 2 p. S638-S639
2 p.
 artikel
7 C.01.02 Disease severity and treatment-resistance: unraveling the treatment options in depression Thase, M.
 2010
 20 Supplement 2 p. S637-
1 p.
 artikel
8 C.10.02 Late-life depression – do we diagnose and treat correctly? Topinková, E.
 2010
 20 Supplement 2 p. S644-
1 p.
 artikel
9 C.12.0l Restoring circadian rhythms: a new way to successfully manage depression Gorwood, P.
 2010
 20 Supplement 2 p. S646-
1 p.
 artikel
10 Contents 2010
 20 Supplement 2 p. OBC-
1 p.
 artikel
11 CSF neurochemicals during tryptophan depletion in individuals with remitted depression and healthy controls Moreno, Francisco A.
 2010
 20 Supplement 2 p. 18-24
7 p.
 artikel
12 C.11.02 Using pharmacological insights to inform real-life decision making – part 2 Fagiolini, A.
 2010
 20 Supplement 2 p. S645-
1 p.
 artikel
13 ECNP Announcement: Research Grant 2010
 20 Supplement 2 p. II-
1 p.
 artikel
14 ECNP Announcement: Young Scientists in Amsterdam 2010 2010
 20 Supplement 2 p. II-
1 p.
 artikel
15 ECNP Calendar of Events 2010
 20 Supplement 2 p. I-
1 p.
 artikel
16 ECNP Calendar of Events 2010
 20 Supplement 2 p. I-
1 p.
 artikel
17 Endogenous cannabinoids in post-mortem brains of Cloninger type 1 and 2 alcoholics Lehtonen, Marko
 2010
 20 Supplement 2 p. 245-252
8 p.
 artikel
18 E.06.01 The stroke patient as a challenge for the psychiatrist Starkstein, S.
 2010
 20 Supplement 2 p. S212-
1 p.
 artikel
19 Heroin-assisted treatment in the Netherlands: History, findings, and international context Blanken, Peter
 2010
 20 Supplement 2 p. S105-S158
54 p.
 artikel
20 Increased voluntary ethanol consumption and c-Fos expression in selected brain areas induced by fear memory retrieval in ethanol withdrawn rats Bertotto, María Eugenia
 2010
 20 Supplement 2 p. 568-581
14 p.
 artikel
21 In vivo potentiation of reboxetine and citalopram effect on extracellular noradrenaline in rat brain by α2-adrenoceptor antagonism Ortega, Jorge E.
 2010
 20 Supplement 2 p. 813-822
10 p.
 artikel
22 Mazindol attenuates ketamine-induced cognitive deficit in the attentional set shifting task in rats Nikiforuk, Agnieszka
 2010
 20 Supplement 2 p. 37-48
12 p.
 artikel
23 Metoclopramide as pharmacological tool to assess vasopressinergic co-activation of the hypothalamus–pituitary–adrenal (HPA) axis: A study in healthy volunteers Jacobs, G.E.
 2010
 20 Supplement 2 p. 866-874
9 p.
 artikel
24 Outcomes of 1014 naturalistically treated inpatients with major depressive episode Seemüller, Florian
 2010
 20 Supplement 2 p. 346-355
10 p.
 artikel
25 P.7.a.002 A controlled family study of children with DSM-IV bipolar-I disorder Biederman, J.
 2010
 20 Supplement 2 p. S611-
1 p.
 artikel
26 P.1.a.018 Alzheimer's disease risk and polymorphisms of the DHCR24 gene Feher, A.
 2010
 20 Supplement 2 p. S222-S223
2 p.
 artikel
27 P.6.a.008 Changes in alcohol use following flood disaster according to pre-disaster alcohol use: a 2-year prospective study Shin, J.
 2010
 20 Supplement 2 p. S574-S575
2 p.
 artikel
28 P.4.a.013 Critical elements of cognitive behavioural therapy (CBT) for panic disorder with agoraphobia: a preliminary examination of the influence of exposure Gloster, A.T.
 2010
 20 Supplement 2 p. S527-S528
2 p.
 artikel
29 P.5.a.001 Disease system analysis approach to model Alzheimer's disease progression in patients on stable acetylcholine esterase inhibitor therapy Gomeni, R.
 2010
 20 Supplement 2 p. S550-
1 p.
 artikel
30 P.2.009 Adolescent and adult male Wistar rats exposed to postnatal maternal separation differ in voluntary ethanol intake Daoura, L.
 2010
 20 Supplement 2 p. S36-
1 p.
 artikel
31 P.5.a.004 Effect of food supplement F containing ferulic acid and angelica archangelica on behavioural disorder of dementia Kanaya, K.
 2010
 20 Supplement 2 p. S552-
1 p.
 artikel
32 P.3.a.033 Electrophysiological measures and clinical scales in schizophrenia and bipolar disorder Domján, N.
 2010
 20 Supplement 2 p. S447-S448
2 p.
 artikel
33 P.4.a.010 Evaluation of the pharmacokinetics and clinical tolerability of the novel anxiolytic BNC210 in healthy volunteers Kremmidiotis, G.
 2010
 20 Supplement 2 p. S526-
1 p.
 artikel
34 P.3.a.002 Evaluation of theta burst stimulation on the resistant auditory hallucinations: a pilot study Sidhoumi, D.
 2010
 20 Supplement 2 p. S430-S431
2 p.
 artikel
35 P.3.a.016 Importance of demographic factors and neuropsychological functioning in schizophrenic patients treated with olanzapine Krysta, K.
 2010
 20 Supplement 2 p. S438-S439
2 p.
 artikel
36 P.2.a.019 Memory and executive functions in patients treated with vagus nerve stimulation for refractory depression Desbeaumes, V.
 2010
 20 Supplement 2 p. S344-
1 p.
 artikel
37 P.3.019 A meta-analysis of neuroimaging predictors of transition to psychosis Smieskova, R.
 2010
 20 Supplement 2 p. S78-
1 p.
 artikel
38 P.1.a.003 Pharmacogenetic study on metabolic syndrome induced by atypical antipsychotics and mood stabilizers Bondolfi, G.
 2010
 20 Supplement 2 p. S214-
1 p.
 artikel
39 P.2.a.002 The potential of the nicotinic channel blocker tc-5214 as augmentation treatment in patients with major depression Dunbar, G.
 2010
 20 Supplement 2 p. S334-
1 p.
 artikel
40 P.2.a.033 Therapy of anxiety-depressive disorders in outpatient cardiologic practice Garganeyeva, N.
 2010
 20 Supplement 2 p. S352-S353
2 p.
 artikel
41 P.2.a.005 Unplanned versus planned suicide attempters: motives, methods, and mental disorders in a Korea-based community sample Jeon, H.J.
 2010
 20 Supplement 2 p. S336-
1 p.
 artikel
42 P.5.a.018 Validity of semantic memory test as predictor of change in ADAS-cog scores in mild cognitive impairment Kornsey, E.
 2010
 20 Supplement 2 p. S560-
1 p.
 artikel
43 P.7.b.003 Association study of the serotonin 1A receptor gene and tryptophan hydroxylase 2 gene in ADHD Kwon, Y.
 2010
 20 Supplement 2 p. S619-S620
2 p.
 artikel
44 P.4.b.008 Beta-adrenoceptor stimulation by isoproterenol promotes olfactory fear conditioning in rats Pavesi, E.
 2010
 20 Supplement 2 p. S534-
1 p.
 artikel
45 P.6.b.002 Can behaviour during computer assisted self-infusion of ethanol (CASE) predict the future risk for addiction? Mick, I.
 2010
 20 Supplement 2 p. S577-
1 p.
 artikel
46 P.3.b.007 Epistasis between variations located in TAAR6 and HSP-70 genes toward schizophrenia and response to antipsychotics Jun, T.
 2010
 20 Supplement 2 p. S455-S456
2 p.
 artikel
47 P.3.b.010 Examination of nociceptive behaviour and stress reactivity in susceptibility gene mutant models of schizophrenia O'Tuathaigh, C.
 2010
 20 Supplement 2 p. S457-S458
2 p.
 artikel
48 P.2.b.002 Risperidone, an atypical antipsychotic, enhances the effect of antidepressant drugs in animal models of depression Rogoz, Z.
 2010
 20 Supplement 2 p. S354-
1 p.
 artikel
49 P.1.b.010 Skin conductance and electromyographic responses to different auditory stimuli in patients with schizophrenia Bilgic, V.
 2010
 20 Supplement 2 p. S232-S233
2 p.
 artikel
50 P.2.b.012 Transcriptional changes of BDNF and clock genes in the rat prefrontal cortex following acute agomelatine administration Calabrese, F.
 2010
 20 Supplement 2 p. S360-
1 p.
 artikel
51 P.4.b.005 Type-2 cannabinoid receptor (CB2r) overexpression results in reduced response to anxiogenic-like stimuli and impaired anxiolytic action of alprazolam García-Gutiérrez, M.
 2010
 20 Supplement 2 p. S532-
1 p.
 artikel
52 P.6.c.010 Abuse potential of nabiximols oromucosal spray compared with dronabinol and placebo in recreational marijuana users Schoedel, K.A.
 2010
 20 Supplement 2 p. S587-
1 p.
 artikel
53 P.2.c.001 Adding an atypical antipsychotic drug induced a rapid increase of plasma BDNF levels in refractory depression Yoshimura, R.
 2010
 20 Supplement 2 p. S367-S368
2 p.
 artikel
54 P.2.c.032 Adjunctive aripiprazole in major depressive disorder (MDD): efficacy and predictors of remission Nelson, J.C.
 2010
 20 Supplement 2 p. S386-
1 p.
 artikel
55 P.3.c.041 A randomized, double-blind study of paliperidone palmitate and risperidone long-acting therapy in schizophrenia Pandina, G.
 2010
 20 Supplement 2 p. S481-S482
2 p.
 artikel
56 P.3.c.055 Asenapine: short-term tolerability, safety, and pharmacokinetic profile in older patients with psychosis Dubovsky, S.
 2010
 20 Supplement 2 p. S489-S490
2 p.
 artikel
57 P.1.c.023 Assessment of benzodiazepines-valproic acid pharmacokinetic interaction in adult epileptic patients: population approach Vucicevic, K.
 2010
 20 Supplement 2 p. S247-S248
2 p.
 artikel
58 P.3.c.069 Dosage patterns – lessons learned from the e-STAR database in Czech Republic Cesková, E.
 2010
 20 Supplement 2 p. S497-S498
2 p.
 artikel
59 P.1.c.020 Effect of mycophenolate mofetil on behavioural and neuroimaging outcomes in transient focal cerebral ischemia in rats Chauhan, A.
 2010
 20 Supplement 2 p. S246-
1 p.
 artikel
60 P.2.c.035 Effect of phospholipase C enzyme gene and environmental factors on antidepressant treatment in Han Chinese population Zhang, Z.J.
 2010
 20 Supplement 2 p. S388-
1 p.
 artikel
61 P.4.c.001 Efficacy of repetitive transcranial magnetic stimulations in the management of obsessive compulsive disorder EL-Sawy, H.
 2010
 20 Supplement 2 p. S541-S542
2 p.
 artikel
62 P.7.c.002 Efficacy of risperidone on the core symptoms of autistic disorder Kolar, D.
 2010
 20 Supplement 2 p. S621-
1 p.
 artikel
63 P.1.c.010 Lithium reduces neuropathic pain: involvement of opioid system Banafshe, H.r.
 2010
 20 Supplement 2 p. S240-S241
2 p.
 artikel
64 P.3.c.028 Olanzapine in treatment of delusional disorders Zivkovic, N.
 2010
 20 Supplement 2 p. S473-S474
2 p.
 artikel
65 P.3.c.011 Olanzapine long-acting injection vs oral olanzapine in schizophrenia outpatients: a 2-year, randomized, open-label study Detke, H.
 2010
 20 Supplement 2 p. S464-
1 p.
 artikel
66 P.1.c.051 Predictive modeling – impact of varying doses and different formulations on receptor occupancy profile for quetiapine Nyberg, S.
 2010
 20 Supplement 2 p. S264-
1 p.
 artikel
67 P.3.c.038 Quetiapine and norquetiapine efficacy in axiety and depression in major psychosis: a pharmacokinetic approach Mauri, M.
 2010
 20 Supplement 2 p. S480-
1 p.
 artikel
68 P.2.c.018 Safety of quetiapine for treatment of insomnia in patients with major depressive disorder Lee, S.
 2010
 20 Supplement 2 p. S377-S378
2 p.
 artikel
69 P.1.c.054 Sustained administration of bupropion enhances serotonergic and noradrenergic neurotransmission in the rat hippocampus Ghanbari, R.
 2010
 20 Supplement 2 p. S265-S266
2 p.
 artikel
70 P.3.c.014 The impact of the subjective response to antipsychotics on the course of illness in schizophrenic patients Murawiec, S.
 2010
 20 Supplement 2 p. S465-S466
2 p.
 artikel
71 P.1.c.037 The profile of attentional deficits in schizophrenia: implications for pharmacotherapy Wesnes, K.A.
 2010
 20 Supplement 2 p. S256-
1 p.
 artikel
72 P.3.d.010 Antipsychotic drugs induce dopamine type 2 receptor mediated suppression of neuronal firing in the rat nucleus incertus Rajkumar, R.
 2010
 20 Supplement 2 p. S502-S503
2 p.
 artikel
73 P.1.d.004 Cyclooxygenase-2 inhibition by nimesulide may reduce the incidence of pentylenetetrazole-induced seizure in mice Mesdaghinia, A.
 2010
 20 Supplement 2 p. S275-S276
2 p.
 artikel
74 P.6.d.023 Effects of different schedules of neuroleptic treatment on mesolimbic and nigrostriatal dopaminergic supersensitivity Frussa-Filho, R.
 2010
 20 Supplement 2 p. S601-
1 p.
 artikel
75 P.3.d.003 Effects of olanzapine on structure and function of brain tissue biomolecules during unpredictable chronic mild stress: an Fourier transform mid-infrared spectroscopic study Komsuoglu, I.
 2010
 20 Supplement 2 p. S499-
1 p.
 artikel
76 P.1.024 Depressive disorder moderates the effect of fat mass and obesity-associated gene (FTO) on body mass index (BMI) Rivera, M.
 2010
 20 Supplement 2 p. S21-S22
2 p.
 artikel
77 P.6.d.026 Impaired color vision in recreational stimulant users Hulka, L.
 2010
 20 Supplement 2 p. S603-
1 p.
 artikel
78 P.2.d.011 Low dose pipamperone, enhancing antidepressant effect of citalopram, occupies 5HT2A 50–60% leaving D2 nearly drug free Buntinx, E.
 2010
 20 Supplement 2 p. S396-S397
2 p.
 artikel
79 P.1.d.001 Marinobufagenin, an endogenous Na pump inhibitor, is implicated in social behavior of mice Kashkin, V.A.
 2010
 20 Supplement 2 p. S274-
1 p.
 artikel
80 P.1.d.018 Memory consolidation via membrane glucocorticoid receptors that can be blocked by cannabinoid receptor antagonists Hauer, D.
 2010
 20 Supplement 2 p. S283-S284
2 p.
 artikel
81 P.1.d.015 Postponed influence of neonatal arginine-vasopressin and the arginine-vasopressin fragment Ac-D-MPRG administration to young white rats on behaviour Kim, P.
 2010
 20 Supplement 2 p. S282-
1 p.
 artikel
82 P.2.d.003 The omega-3 polyunsaturated fatty acid docosahexaenoic acid suppresses neuroinflammatory responses and induces heme oxygenase-1 expression in BV-2 microglia Su, K.
 2010
 20 Supplement 2 p. S392-S393
2 p.
 artikel
83 P.6.d.014 The severity of morphine abstinence correlates with brain FADD phosphorylation: interaction with α2-adrenoceptors Ramos-Miguel, A.
 2010
 20 Supplement 2 p. S596-
1 p.
 artikel
84 P.6.d.009 Tobacco and suicidal ideation Millares, M. Vidal
 2010
 20 Supplement 2 p. S593-
1 p.
 artikel
85 P.1.e.007 Abnormal cortical neurotransmitter levels in young people at familial risk of depression Taylor, M.J.
 2010
 20 Supplement 2 p. S292-
1 p.
 artikel
86 P.7.e.002 European professionals' attitudes and practices in the management of ADHD Fitzgerald, M.
 2010
 20 Supplement 2 p. S629-S630
2 p.
 artikel
87 P.3.e.001 Facial emotion recognition deficit in schizophrenia: a replication study in Korean subjects Lee, S.J.
 2010
 20 Supplement 2 p. S507-S508
2 p.
 artikel
88 P.2.e.008 Initial antidepressant monotherapy in bipolar depression is associated with more depressive relapses and switches Valentí, M.
 2010
 20 Supplement 2 p. S406-
1 p.
 artikel
89 P.2.e.022 Lamotrigine adjunctive therapy and possible sleep regulation in adult autism spectrum disorder: a case report Ooga, K.
 2010
 20 Supplement 2 p. S414-S415
2 p.
 artikel
90 P.2.e.005 Mood stabilisers and atypical antipsychotics in the long-term treatment of bipolar disorder Altamura, A.C.
 2010
 20 Supplement 2 p. S404-S405
2 p.
 artikel
91 P.5.e.001 Patient characteristics for misdiagnosed delirium at psychiatric consultation in a university hospital Yun, K.W.
 2010
 20 Supplement 2 p. S567-S568
2 p.
 artikel
92 P.5.e.004 The impact of site rater monitoring and refresher training on enrollment in a mild cognitive impairment phenotype trial Friedmann, B.
 2010
 20 Supplement 2 p. S569-S570
2 p.
 artikel
93 P.3.e.006 The utility of the MMPI-2 and PAI for discriminating the patients with schizophrenia and depression in Korea Park, M.C.
 2010
 20 Supplement 2 p. S510-S511
2 p.
 artikel
94 P.2.f.005 Pharmacological treatment in bipolar I and II disorders Gómez, N. Varela
 2010
 20 Supplement 2 p. S420-
1 p.
 artikel
95 P.1.f.005 Risk of development of premenstrual symptoms is associated with a traitlike negative bias in perception of life events Gonda, X.
 2010
 20 Supplement 2 p. S308-
1 p.
 artikel
96 P.3.f.008 The relationship between insight and psychosis in schizophrenic Romanian patients Crisan, C.
 2010
 20 Supplement 2 p. S517-S518
2 p.
 artikel
97 P.1.g.017 American ginseng improves human neurocognitive function: a randomized, double-blind, placebo-controlled, crossover study Scholey, A.
 2010
 20 Supplement 2 p. S318-
1 p.
 artikel
98 P.1.g.014 Cognitive and neurophysiological performance following scopolamine and ketamine administration in a crossover study Levy-Cooperman, N.
 2010
 20 Supplement 2 p. S316-
1 p.
 artikel
99 P.2.023 Glycine transporter 1 disruption restricted to the nucleus accumbens is sufficient to enhance latent inhibition Peleg-Raibstein, D.
 2010
 20 Supplement 2 p. S47-S48
2 p.
 artikel
100 P.1.h.007 Influence of compensation satisfaction on change of health-related quality of life after a flood Min, S.
 2010
 20 Supplement 2 p. S326-
1 p.
 artikel
101 P.2.h.003 Suicide attempts in a mental health unit of Galicia Traba, B. Pórtela
 2010
 20 Supplement 2 p. S428-S429
2 p.
 artikel
102 PL.02.01 CSF biomarkers in Alzheimer's disease – use in clinical diagnosis and to monitor treatment effects Blennow, K.
 2010
 20 Supplement 2 p. S159-
1 p.
 artikel
103 P.1.009 Mice with decreased vesicular glutamate transporter VGLUT1 levels show an altered presynaptic 5-HT function García-García, A.L.
 2010
 20 Supplement 2 p. S9-S10
2 p.
 artikel
104 P.1.025 Molecular imaging of beta-2 subunit containing nicotinic acetylcholine receptors in major depressive disorder Saricicek, A.
 2010
 20 Supplement 2 p. S22-
1 p.
 artikel
105 P.1.006 Neurogenic and chronic behavioural effects of fluoxetine are attenuated in p11 KO mice Egeland, M.
 2010
 20 Supplement 2 p. S6-S7
2 p.
 artikel
106 P.3.002 Placebo response in trials for acute mania: a double-edged sword Bonnin, M.
 2010
 20 Supplement 2 p. S63-
1 p.
 artikel
107 P.2.026 Serotonin–dopamine interaction in reward: microdialysis and intracranial self-stimulation Prins, J.
 2010
 20 Supplement 2 p. S50-
1 p.
 artikel
108 P.3.016 Temporal lobe grey matter volume in schizophrenia is influenced by glycogen synthase kinase 3-beta activity Poletti, S.
 2010
 20 Supplement 2 p. S75-S76
2 p.
 artikel
109 Reduced platelet G protein-coupled receptor kinase 2 in major depressive disorder: Antidepressant treatment-induced upregulation of GRK2 protein discriminates between responder and non-responder patients García-Sevilla, Jesús A.
 2010
 20 Supplement 2 p. 721-730
10 p.
 artikel
110 Retrograde facilitation of verbal memory by trihexyphenidyl in healthy elderly with and without the APOE ε4 allele Pomara, Nunzio
 2010
 20 Supplement 2 p. 467-472
6 p.
 artikel
111 S41744, a dual neurokinin (NK)1 receptor antagonist and serotonin (5-HT) reuptake inhibitor with potential antidepressant properties: A comparison to aprepitant (MK869) and paroxetine Millan, Mark J.
 2010
 20 Supplement 2 p. 599-621
23 p.
 artikel
112 S.10.01 Biological pathways underpinning chronic fatigue, somatisation and psychosomatic symptoms Maes, M.
 2010
 20 Supplement 2 p. S179-
1 p.
 artikel
113 S.24.02 Cognitive endophenotypes in schizophrenia Aukes, M.F.
 2010
 20 Supplement 2 p. S199-S200
2 p.
 artikel
114 S.07.02 Cued but not contextual fear conditioning impairment in the NMDA receptor subunit NR1-DbhCre transgenic mice Solecki, W.
 2010
 20 Supplement 2 p. S171-S172
2 p.
 artikel
115 S.15.01 Data mining and neuroinformatics Nielsen, F.A.
 2010
 20 Supplement 2 p. S184-
1 p.
 artikel
116 S.27.04 Harmful psychiatric effects of plant cannabinoids in humans Henquet, C.
 2010
 20 Supplement 2 p. S206-
1 p.
 artikel
117 S.12.05 5-HT2C receptor ligands in the treatment of obesity and type 2 diabetes Heisler, L.K.
 2010
 20 Supplement 2 p. S182-
1 p.
 artikel
118 S.04.03 Inositol monophosphatase: drug target or false alarm? Singh, N.
 2010
 20 Supplement 2 p. S166-
1 p.
 artikel
119 S.4.01 Molecular drug targets for bipolar disorders Manji, H.
 2010
 20 Supplement 2 p. S87-S89
3 p.
 artikel
120 S.18.05 Neurobiological mechanisms of hyperactivity in anorexia nervosa Adan, R.A.H.
 2010
 20 Supplement 2 p. S190-S191
2 p.
 artikel
121 S.20.05 NIMH/FDA guidelines for clinical trials for cognition in schizophrenia: how much have we advanced? Marder, S.
 2010
 20 Supplement 2 p. S194-
1 p.
 artikel
122 S.15.04 Systems biology approaches to study Parkinson's disease in C. elegans models Wong, G.
 2010
 20 Supplement 2 p. S185-
1 p.
 artikel
123 S.03.05 The muscarinic receptor family: potential targets for the treatment of symptoms associated with schizophrenia Felder, C.C.
 2010
 20 Supplement 2 p. S165-
1 p.
 artikel
124 S.24.05 Transgenic mouse models in addiction research Robledo, P.
 2010
 20 Supplement 2 p. S200-S201
2 p.
 artikel
125 The α2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats Semenova, Svetlana
 2010
 20 Supplement 2 p. 731-746
16 p.
 artikel
126 The β3 adrenoceptor agonist, amibegron (SR58611A) counteracts stress-induced behavioral and neurochemical changes Tamburella, Alessandra
 2010
 20 Supplement 2 p. 704-713
10 p.
 artikel
127 The effect of chronic methylphenidate administration on presynaptic dopaminergic parameters in a rat model for ADHD Simchon, Y.
 2010
 20 Supplement 2 p. 714-720
7 p.
 artikel
                             127 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland